Table 1—

Efficacy ofi.v. topotecan (1.5 mg·m-2·day-1, on days 1–5) in second-line small cell lung cancer

First author [ref.]Subjects nCRPROR %SD %Survival weeks#
Eckhardt 9
von Pawel 10
Ardizzoni 11
  • CR: complete response; PR: partial response; OR: odds ratio; SD: stable disease; NR: not reported. #: median. : patients who failed to respond or progressed within 90 days of first-line therapy were termed refractory; +: patients who relapsed after 90 days after first-line therapy were termed sensitive.